archive-com.com » COM » P » PWC.COM

Total: 2203

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Pharma life sciences
    that data Drug companies are using 23andMe s genetics database to shape and speed clinical trials and shave costs off of the process 23andMe has moved into joint development collaborations where there are milestones or the potential for royalties said Emily Drabant Conley 23andMe s director of business development And that is out of a recognition that the data are valuable In March of 2015 23andMe announced the creation of a therapeutics group to be led by Richard Scheller former EVP of research and early development at Genentech In addition to collaborations 23andMe will search for and pursue drug targets on its own Consumers who purchase 23andMe s genotyping kit for 99 and send in their saliva samples get access to an online account to see their ancestry results and uninterpreted raw data Inside that account consumers are presented with a consent form and asked if they want to share their data for research More than 80 of our consumers opt in to participate said Conley Those who opt in are prompted to answer survey questions about prior diagnoses family history and medication use A collaboration with Genentech announced at the start of 2015 is focused on identifying drug targets for Parkinson s disease The majority of the 11 000 genotyped Parkinson s patients in 23andMe s database also provided information about their symptoms and how they ve progressed over time said Conley Working with Genentech 23andMe is narrowing the population of 11 000 Parkinson s patients down to a couple of thousand who are particularly interesting from a drug discovery perspective That group which may include people with very early onset of the disease very fast progression of symptoms or people with known genetic risk factors will undergo a full genome sequencing and a more thorough genetic exploration as part of a clinical trial A collaboration with Pfizer in inflammatory bowel disease IBD turns the 23andMe kit into a patient recruitment tool for research Individuals with an IBD diagnosis such as Crohn s disease or ulcerative colitis are eligible for a free kit in exchange for consenting to share the data with Pfizer They also must fill out short surveys online The goal of the Pfizer study which hopes to enroll 10 000 IBD patients is to use genetics to identify segments of the population that fit a certain profile said Conley For example patients that didn t respond to specific drugs to treat their disease You can think about that from the insurance level but also in how you structure your clinical trial said Conley Another Pfizer collaboration in lupus asks participants to consent to have 23andMe track down their medical records and use that data as part of the research Asked about the next therapeutic frontier for genetics Conley said the treatment of psychiatric disorders such as depression and bipolar disorder could be improved by genetics The number of products available and the wide variation in efficacy and response rates leaves psychiatrists throwing darts at a board

    Original URL path: http://www.pwc.com/us/en/health-industries/health-research-institute/hri-pharma-life-sciences-fda.html (2016-02-10)
    Open archived version from archive


  • Pharmaceutical industry thought leadership from PwC
    its 13th issue of the Asia Pacific Health Industries Newsletter 2015 State of the Internal Audit Profession Finding true north in a period of rapid transformation April 16 2015 PwC s 2015 State of the Internal Audit Profession Study reflects the views of more than 1300 chief audit executives senior management and board members Asia Pacific Health Industries Newsletter December 23 2014 PwC s Global Health Industries network is pleased to present you with its 12th issue of the Asia Pacific Health Industries Newsletter Asia Pacific Health Industries Newsletter July 2014 July 25 2014 In this edition we highlight recent developments in Asia and Australia including changes in China s compliance and pricing environment pharmaceutical deals in South Korea and India digital health Big Data and tax developments in Australia Hong Kong China and Singapore R D outsourcing in hi tech industries A research study June 26 2014 PwC researches pharma relationship performance in large scale clinical outsourcing and lessons from R D outsourcing in other hi tech industries Managing innovation in pharma May 16 2014 This PwC publications surveys pharmaceutical executives across the pharmaceutical value chain about the challenges on innovation in the sector Transfer pricing symptoms of chronic industry challenges October 23 2013 This article lays out these and other key issues you may be facing and offers guidance on how to bring your transfer pricing strategies up to date while managing the expectations of multiple stakeholders Asia Pacific Pharma Life Sciences Newsletter March 2013 March 22 2013 This PwC publication provies news and analysis for pharmaceutical biotechnology medical device diagnostic and healthcare companies Pharma 2020 report From vision to decision November 15 2012 In this report we focus on how companies can reach 2020 in a position to benefit from more favourable conditions thereafter Asia Pacific Pharma Life Sciences Newsletter August 2012 August 01 2012 Asia Pacific Pharma Newsletter Issue 9 covers compliance updates in Australia government price cuts in the region and tax issues in Australia China India Taiwan and Singapore Asia Pharmaceutical Newsletter April 2012 April 30 2012 This PwC newsletter includes reports on the recent Indian and Singapore Budgets and the implications for multinationals and the local Pharma and Healthcare sectors Taking advantage of the Medtech market potential in India success will hinge on operating model innovation April 30 2012 PwC recently surveyed executives from leading global and domestic Medtech companies with India operations representing 1 3 billion in revenues in India or roughly 40 of the 3 billion Indian market Their responses combined with in depth interviews and PwC s research and experience in the industry provide insight on how to succeed in India Introducing the Pharma 2020 series January 16 2012 PwC s Pharma 2020 series reports look into the future of the Pharmaceuticals and Life Sciences value chain and they include an analysis of the strategies needed to compete successfully in the future Diagnostics 2011 M A surges companion diagnostics accelerate and early detection offers new prospects December 05 2011 PwC

    Original URL path: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/publications.html (2016-02-10)
    Open archived version from archive

  • Mike Swanick
    Our leadership team Code of conduct Corporate responsibility Network governance Our contribution to the debate Genesis Park Diversity and inclusion Analyst relations Alumni Member firms worldwide Live events and discussions Strategy Research insights View featured Browse by issue Browse by industry Browse by service Monthly highlights Spotlight The CEO agenda CEO insights blog Careers About PwC Technology careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Mike Swanick Global Pharmaceuticals and Life Sciences leader Summary Mike has been with PwC for 28 years and a partner for 19 years He is and has been the Firm s Global and US tax leader of the Pharmaceutical and Life Sciences Practice for the last 6 years Previously he was the Partner in Charge of International Tax Services in Philadelphia from 2000 to 2002 Mike has extensive experience working with international and domestic pharmaceutical and life science companies as well as manufacturing medical device and chemical companies Mike has a BS from Saint Joseph s University and a MS from Villanova University He is a CPA and spent 3 years based in London where he led the Firm s US Corporate Tax Consulting groups and 2 years in Brussels where he advised many publicly traded US and EU companies on cross border transactions Selected Experience Lead Tax Partner on numerous multinational tax clients Extensive experience with issues facing pharmaceutical medical device and biotechnology

    Original URL path: http://www.pwc.com/gx/en/contacts/m/mike-swanick.html (2016-02-10)
    Open archived version from archive

  • Douglas Strang
    Global Annual Review Our leadership team Code of conduct Corporate responsibility Network governance Our contribution to the debate Genesis Park Diversity and inclusion Analyst relations Alumni Member firms worldwide Live events and discussions Strategy Research insights View featured Browse by issue Browse by industry Browse by service Monthly highlights Spotlight The CEO agenda CEO insights blog Careers About PwC Technology careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Douglas Strang Global Pharmaceuticals and Life Sciences Advisory leader Summary Doug leads the global and US advisory teamS at PwC focussed on the pharmaceutical and life sciences industry Based in Philadelphia he has over 25 years of experience in the Health Industries Doug is responsible for executing the Firm s industry strategy as well as ensuring that the pharmaceutical and life science practice possesses the skills and capabilities to meet changing client needs He also works closely with PwC s Health Services practice to help clients manage the changing healthcare landscape and convergence across the sectors Selected Experience Doug is a recognised expert in many areas of the pharmaceutical industry and has served as an Arbitrator several times on complex business and other issues in dispute between organizations He has served as the Lead Partner on many complex engagements involving Government Programmes including Department of Justice investigations Compliance Assessments involving Medicaid and Medicare Drug Pricing Programmes and Sales and Marketing compliance

    Original URL path: http://www.pwc.com/gx/en/contacts/d/douglas-strang.html (2016-02-10)
    Open archived version from archive

  • Erik Bouwman
    Network governance Our contribution to the debate Genesis Park Diversity and inclusion Analyst relations Alumni Member firms worldwide Live events and discussions Strategy Research insights View featured Browse by issue Browse by industry Browse by service Monthly highlights Spotlight The CEO agenda CEO insights blog Careers About PwC Technology careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Erik Bouwman Global Pharmaceuticals and Life Sciences Tax leader Summary Erik leads the global Tax team at PwC focussed on the pharmaceuticals and life sciences industry Based in Amsterdam Erik brings almost 25 years of experience advising domestic and international companies on corporate income tax Besides his client facing roles within PwC Erik has been a member of the Tax HRS management board for PwC between 2010 and July 2013 with management responsibility for the corporate tax practice of PwC in the Netherlands dealing with Public Interest Entities Currently Erik is also PwC s Business Transformation Leader Erik has authored several articles on international and domestic tax issues Topics dealt with include international tax structuring and participation exemption Selected Experience Erik advises his clients on Intellectual Property planning techniques Value Chain Transformation planning finance structures International Tax Structuring and deal structuring Examples of recent projects are Structuring acquisitions for US multinationals into Europe Setting up Dutch Innovation box regimes Leveraged acquisition structuring Implementation of Hybrid instruments Loss renewal for Dutch companies Areas

    Original URL path: http://www.pwc.com/gx/en/contacts/e/erik-bouwman.html (2016-02-10)
    Open archived version from archive

  • Peter Kartscher
    industry Browse by service Monthly highlights Spotlight The CEO agenda CEO insights blog Careers About PwC Technology careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Peter Kartscher Global Pharmaceuticals and Life Sciences Assurance Leader Summary Peter leads the global assurance team at PwC focused on the pharmaceuticals and life sciences industry He is currently based in Israel and has over 20 years of experience in providing assurance services to listed companies in Germany the UK and Switzerland Peter has worked predominantly with pharmaceutical and life sciences clients in the last 10 years Peter has a diploma in economics from the University of Hamburg is a German Certified Public Auditor Wirtschaftsprüfer and German Certified Tax Expert Steuerberater and has lived and worked in Germany the UK and most recently in

    Original URL path: http://www.pwc.com/gx/en/contacts/p/peter-kartscher.html (2016-02-10)
    Open archived version from archive

  • Pharmaceutical services: Index of services: PwC
    changes in the Pharma sector Compliance Monitoring and Program Development Services How can pharmaceutical and life sciences companies improve monitoring techniques to anticipate and mitigate compliance risk Corporate integrity agreement and independent review organisation services How can pharmaceutical and life sciences companies effectively meet the challenges of negotiating and implementing a corporate integrity agreement Drug safety and pharmacovigilance advisory services How can pharmaceutical and life sciences companies effectively implement proactive pharmacovigilance and drug safety programs Good clinical practice services How can pharmaceutical and life sciences companies sustain compliance with good clinical practice requirements Government price reporting compliance services How can pharmaceutical and life sciences companies comply with the increasing demands of government price reporting Integrated R D Operations and Business Planning How can an integrated operations and business planning framework increase the productivity of an organization s R D Internal audit services How can pharmaceutical and life sciences companies optimize the internal audit function in a rapidly changing risk environment Licensing management and contract compliance services The pharmaceutical industry constantly faces pressure to develop new products and bring them to market The high cost of R D as well as market demand makes it crucial for the players in the industry to form strategic alliances often through licensing co promotion and co development agreements Licensing management and contract compliance services The pharmaceutical industry constantly faces pressure to develop new products and bring them to market The high cost of R D as well as market demand makes it crucial for the players in the industry to form strategic alliances often through licensing co promotion and co development agreements Pharma Outsourcing Services In an atmosphere of declining research and development R D productivity mounting pricing pressure and changing regulatory requirements global pharmaceutical and life sciences companies face increasing challenges to achieve and maintain profitable growth Global pharmaceutical outsourcing offers companies an opportunity to face these challenges By forming strategic relationships with outsourcing partners companies can focus on core competencies access specialised expertise achieve cost saving benefits and reduce burn rates that lead directly to greater shareholder value Process Analytical Technology PAT services Process Analytical Technologies PAT and Quality by Design QbD Sales and marketing compliance services PricewaterhouseCoopers s experienced professionals have thorough knowledge of sales and marketing operations and can recommend the most effective practices to mitigate compliance risk Our in depth knowledge in compliance risk analysis enables us to rapidly and effectively facilitate a compliance assessment of the major sales and marketing activities used to promote products State level reporting compliance services Our deep technology and data management experience will help you better leverage existing information to solve your state reporting and other compliance related challenges from disparate and vast data sources Supply Chain and Distribution Manufacturing Services Are you unlocking the value of your supply chain Supply chain services for new entrants Building or scaling a business is full of challenges From obtaining the required funding attracting and retaining the right skills to building relationships with key partners Wholesaler

    Original URL path: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/services/services-index.html (2016-02-10)
    Open archived version from archive

  • Case studies and projects: Pharmaceuticals and life sciences: PwC
    Browse by service Monthly highlights Spotlight The CEO agenda CEO insights blog Careers About PwC Technology careers Employer of choice Our history PwC Professional Employability Aspire to lead PwC s series on leadership and gender equality Country job search Explore careers with Strategy Press room Facts and figures Press contacts Analyst relations Global International PwC Sites Commonly visited PwC sites Global Australia Brazil Canada China Hong Kong France Germany India Italy Japan Mexico Middle East Netherlands Russia Singapore South Africa South Korea Spain Sweden Switzerland United Kingdom United States Complete list of PwC territory sites Case studies and projects IT compliance in the cloud Ensuring pharmaceutical supply chain effectiveness cost reduction in finishing packing operations Designing and executing a risk based computerised system validation strategy for a biotech start up implementing a cloud based ERP Ensuring pharmaceutical supply chain effectiveness creating supply chain infrastructure outside local market Finance transformation program results in a smarter control environment Introducing a new management and reporting concept to improve financial transparency and control Maximising revenue growth commercial due diligence on a diagnostics business for a UK business development agency Maximising revenue growth prioritising R D investment opportunities Maximising revenue growth assessing the potential value and proposed licensing terms for a preclinical anti viral Providing independent assurance in pharma and life sciences with internal audit Replacing the IT infrastructure provider R D productivity and the innovation deficit designing constructing and implementing a new operating model for R D R D productivity and the innovation deficit virtual R D Pharmaceuticals and life sciences Services Index of services Case studies Publications Pharma and life sciences tax news Medical Devices tax news KnowledgeLine Pharma 2020 series Video Library Press room Events Webcasts Contacts Health industries Contacts Mike Swanick Mike Swanick Global Pharmaceuticals and Life Sciences leader View complete

    Original URL path: http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/case-studies.html (2016-02-10)
    Open archived version from archive



  •